Shaikh MP, et al. - In pathologic T3 or margin-positive prostate cancer, a meta-analysis of randomized controlled trials (RCTs) was done to compare adjuvant radiotherapy (ART) vs a wait-and-see (WS) strategy. It was observed that ten-year metastasis-free survival was significantly improved with ART vs WS. In addition, they found that biochemical progression-free, clinical progression-free, and hormone-free survival were improved with ART. In ART, grade 2 or higher gastrointestinal and genitourinary toxicities were more common. Results of this study suggested that ART should be offered to patients with these high-risk features.